Retinal Manifestations of Systemic Disease

Steven Ferrucci, OD, FAAO
Chief, Optometry Sepulveda VA
Professor, SCCO/MBKU

Retinal Plaques
• Several different types of plaques can often be visualized in the retinal vasculature
• Pt is typically elderly, has HTN, CAD, hypercholesterolemia/hyperlipidemia, and/or atherosclerotic disease
• Often totally asymptomatic and found on routine exam

RISK FACTORS
• Age
• HTN
• Vascular disease
• Past vascular surgery
• SMOKING
• High TOTAL cholesterol
• Men> women

Prevalence
• Beaver Dam Eye Study: 1.3%
  • smoking, HTN and DM
  • 9x more likely after age 75 vs. 43-54
    • after 75, 3.1% prevalence
    • Equates to 1.2 million people with emboli 43-86
    • >450,000 are 75-86
    • Fatal stroke 3x as likely over 8 years in pts with emboli, adjusting for other factors
• OD>OS
• Bilateral very infrequently

Prevalence
• Blue Mountain Eye Study: 1.4%
  • HTN, smoking, Vascular disease
• LA Latino Eye Study: 0.4%
  • Smoking, CAD, h/o MI, HTN
• Singapore Eye Study: 0.6%
  • Smoking, high cholesterol, h/o angina

Retinal Plaques
• May present with amarosis fugax, transient episodes of monocular blindness
• Rarely, may report transient ischemic attack (TIA), which is above with hemiparesis, parasthesia or aphasia
Retinal plaques

• Three different types of plaques, but all share strong association to significant cardiovascular disease
  – HH 80% > fibrino-platelet 14% > calcific 6%

Retinal Plaques

• Cholesterol (Hollenhorst) plaque
  – Most common
  – Shiny yellow-orange in appearance
  – From plaque in the ipsilateral carotid artery
  – Rarely causes occlusion, unless multiple
  – Typically occurs at bifurcations
  – Mobile in nature

Retinal Plaques

• Fibrino-platelet
  – Appear as dull white to gray, long plugs
  – Typically within arterioles, not at bifurcations
  – May break-up and dissolve with time
  – May lead to BRAO or CRAO
  – Often associated with carotid disease or mitral valve insufficiency

Retinal Plaques

• Calcific
  – Appears more whitish than HH
  – Dull, non-reflective, white
  – Classically within arteriole, not at bifurcation
  – Typically immobile
  – Most dangerous, often cause BRAO
  – Often from cardiac atheromas of heart valves

Retinal plaques

• Talc retinopathy
  – Represents an exogenous plaques as opposed to others
  – Appears typically as multiple shiny yellow plaques within capillaries in posterior pole
  – Typically smaller than other plaques
  – Typically seen in IV drug users
  – Rarely cause complications, but reported cases of associated NV and occlusions

Retinal plaques

• No direct management of plaques is needed
• Management is aimed at discovering source of embolus to decrease risk of other emboli, occlusion, or stroke
• Pts need referral to internist for complete physical
**Retinal Plaques**
- Assess risk factors with PCP
  - DN, HTN, lipid panels
- Carotid ultrasound
- MRA: non-invasive image with 2D/3D
- TEE: invasive, probe into esophagus to image heart valves
  - Helpful with calcific
- CTA: CT scan of arteries construct 3D images

**Carotid Ultrasound**
- First line screening test
- ORDER WITHIN TWO WEEKS!!
- Identifies flow rate and % stenosis
- Common, internal, and external
- Only ~20% of asymptomatic emboli will have significant carotid stenosis

**Retinal Plaques**
- **<50-60% occlusion**
  - ORAL TREATMENT
    - Anti-Platelet
      - ASA
    - Anti-coagulation
      - Comadin, platelet
    - Cholesterol meds
  - >70-99%
    - SURGICAL TREATMENT
      - Carotid endarterectomy
      - Angioplasty
      - reduces risk of future stroke!

**Retinal Vein Occlusions**
- BRVO
  - Second most common retinal vascular disorder
  - Often associated with systemic HTN
  - Peak incidence in 5th to 6th decades, with no sex predilection
- CRVO
  - Very visually destructive disease with strong systemic association
  - Typically occurs in men > 50
  - Vision is typically compromised, ranging from moderate to total vision loss

**Is it worth working up these patients?**
- 18% of pts with retinal emboli had internal or common carotid stenosis>75%
- Higher incidence of stroke
  - 8.5% with emboli vs 0.8% w/o per year
- Pts with cholesterol HH emboli have 15% mortality at 1 yr, 29% by year 3, and 54% by 7 years
# Retinal Vein Occlusions

**BRVO**
- Classic presentation is dilated tortuous veins and dot-blot hemes from site of compression to periphery in sector normally drained by that vein
- Can also see flame-shaped hemes and cotton wool spots as hypoxia develops
- Lipid can also develop leading to macula edema

**CRVO**
- Non-ischemic characterized by dot/blot hemes, intra-retinal hemes, and possible macula edema
- Ischemic CRVO presents with dot/blot hemes, flame-shaped hemes, CWS, and gross intra-retinal and macula edema. Also, papillidema commonly present

---

# Ischemic vs non-ischemic CRVO

- IOP often reduced more with ischemic vs. ischemic CRVO
- APD often present with ischemic
- VA generally reduced more with ischemic
  - Rule of thumb: if VA < 20/200 then ischemic.
- In order to know for certain, FA needed
  - Helps to stratify risks, prognosis

---

# Traditional Treatment: BRVO

- Branch Vein Occlusion Study Group concluded that grid laser improves visual outcome in eyes with BRVO and vision 20/40 or worse from macular edema
  - BRVO at least 3 months old
  - VA 20/40 or worse
  - FA within 1 month, demonstrating macula edema and absence of foveal ischemia

---

# Traditional Treatment: CRVO

- Patients with macular edema from CRVO typically do not respond well to FML at all
- CVOS Study: Improvement on appearance, but no gain in acuity
- Big concern is risk for NVG
  - NVG in 14-20% of all CRVO
  - NVG almost 60% of the time in ischemic CRVO

---

# BRVO/CRVO

- Management includes diagnosis and management of underlying etiology
- Most often associated with DM and HTN
- However many other possible etiologies
  - Carotid artery disease
  - Hyperlipidemia/hypercholesterolemia
  - Altered platelet function
  - Coats disease
  - Von-Hippel Lindau
  - Eales’ disease
  - Trauma
BRVO/CRVO

- At minimum, should have
  - BP evaluated
  - Fasting Blood sugars (FBS)/A1c
  - CBC
  - Lipid profile

- Additional tests might include
  - Carotid artery evaluation
  - Cardiac evaluation
  - Additional blood tests
    - ANA
    - RF
    - FTA/ABS
    - ESR

New Treatments: Steroids

- CRVO SCORE
  - ¼ patients receiving IVT had a 15 letter or better improvement in VA at 12 months
  - Pts 5x as likely to have VA improvement vs. observation alone

- BRVO SCORE
  - Almost equal number of patients in laser or steroid group had > 15 letter improvement
  - More complications in IVT group

New Treatments: Anti-VEGF

- CRUISE (CRVO) Study:
  - Vision improved > 15 letters in almost 50% of patients vs. 17% with sham at 6 mos
  - Mean VA gain of almost 15 letters

- BRAVO (BRVO) Study:
  - Vision improved > 15 letters in over 60% of patients vs. 28% with sham
  - Mean VA gain of approx 18 letters
  - Few side effects in either group

Elyea® (afilbercept)

- FDA approved Sept, 2012 for treatment of macula edema secondary to CRVO
- COPERNICUS and GALILEO studies:
  - % of pts gaining 15 letters or more of BCVA
  - Injection q 2 mos for 24 weeks
- COPERNICUS:
  - 56% vs. 12% with sham
  - 17.3 letters gained vs. 4.0 lost with sham
- GALILEO:
  - 60% vs. 22% with sham
  - 18.0 letters gained vs. 3.3 lost with sham

Ozurdex®

- 0.7 mg biodegradable intravitreal dexamethasone insert
- FDA approved for macula edema from BRVO/CRVO
- 853 patients
  - 20-30% gained ≥ 3 lines vs. 7-12% with sham at 6 mos
  - 7.4 mean letter gain vs. 4.9 with sham at 6 mos

CRVO

Most common etiologies varied with age at presentation

- Under age 50
  - Head injury
  - Hyperlipidemia
  - Estrogen, esp. oral contraceptives

- Over age 50
  - HTN
  - DM
  - Chronic lung disease
BRVO/CRVO Treatment

<table>
<thead>
<tr>
<th>Traditional</th>
<th>Now</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Wait and see</td>
<td>• No advantage to wait</td>
</tr>
<tr>
<td>– 3 mos</td>
<td>– 1 week</td>
</tr>
<tr>
<td>– 20/40 or worse</td>
<td>– VA loss?</td>
</tr>
<tr>
<td>• Laser for BRVO</td>
<td>• Anti-VEGF for BRVO</td>
</tr>
<tr>
<td>• No Tx CRVO</td>
<td>• Anti-VEGF for CRVO</td>
</tr>
<tr>
<td>• Evaluate underlying disease</td>
<td>• Evaluate underlying disease</td>
</tr>
</tbody>
</table>

BRVO

- Result of emboli dislodged from elsewhere which travels through the system until a vessel too small for passage is reached
- Arterial occlusion causes anoxia due to lack of oxygenated blood
  - Anoxia causes loss of retinal layers, including NFL through inner nuclear layer

CRAO

- Mechanism similar to BRAO, but larger embolus causes obstruction prior to laminar cribosa, so entire central retinal artery is obstructed
- Pts typically present with sudden painless loss of vision in an eye that was previously thought to be healthy
- Typically pts from 50-80 years of age

BRAO

- Occurs most frequently in superior temporal region of the retina
- Visual acuity and field loss dependent on location and extent of blockage
  - VF loss is classically
    a sharp edged defect
    stopping abruptly
    at the horizontal raphe
- Appearance varies as time progresses
  - Initially, affected arteries narrow and retina becomes hazy
  - Over a few hours, the retinal tissues whitens and appears edematous
  - Segmental optic atrophy may also develop in the affected area

BRAO

- Prognosis depends upon area affected as well as extent of blockage
- Also depends upon prompt therapy, to lesser extent
  - Some studies indicate that if emboli can be dislodged within 1-2 hours, recovery can be complete
  - After this period, initial acuity is not likely to improve
**CRAO**

- Vision typically in the hand motion to counting fingers range
- Most often present with an APD as well
- If a cilioretinal artery is present, there may be a small island of vision that correlates to the area of vascular supply
  - Present in about 10% of eyes
- Can see an embolus in 20-40% of cases

**CRAO**

- Early appearance is that of retinal narrowing and haziness of retinal tissue
- After 1-2 hours, retina appears white and edematous, with a "cherry red" macula, representing the choroidal blood supply to the macula
- With time, the arteries may assume a more normal appearance, with irregular narrowing often the only clue
- Optic atrophy may occur, but NVG is very rare

**CRAO**

- Management often includes attempts to dislodge embolus if pt presents within first 1-2 hours
  - Digital massage, paracentesis to lower IOP, carbogen, anti-thrombotic agents, etc have little to no value
- Management lies in diagnosis and management of underlying systemic disease

**CRAO**

- Immediate ESR needed to rule out GCA if pt over 55
  - Only 2%-5% secondary to GCA in one study
- Most often associated with DM, HTN, and carotid artery disease
  - Many other etiologies including: sickle cell, oral contraceptives, Lupus, Bechets disease, Lyme disease, etc

**BRAO/CRAO**

- Blood pressure
- Lab tests
  - FBS
  - CBC
  - ESR
  - Lipid profile
  - PT/PTT
  - ANA/RF
- Carotid Artery Evaluation
- Cardiac Evaluation
  - Echocardiogram and possible Holter monitor

**BRAO/CRAO**

- Follow-up
  - BRAO: 3-6 mos after ruling out underlying etiology
  - CRAO: follow closely for first 1-3 mos for NVI, then periodically after
    - If NV, then PRP indicated to prevent NVG